

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 October 2011 (06.10.2011)

PCT

(10) International Publication Number
WO 2011/123029 A1

(51) International Patent Classification:
G01N 33/543 (2006.01)

(21) International Application Number:
PCT/SE2011/050343

(22) International Filing Date:
29 March 2011 (29.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1050302-7 30 March 2010 (30.03.2010) SE

(71) Applicant (for all designated States except US): **GE HEALTHCARE BIO-SCIENCES AB** [SE/SE]; Patent Department, Björkgatan 30, S-751 84 Uppsala (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KARLSSON, Robert** [SE/SE]; GE Healthcare, Rapskatan 23, S-751 84 Uppsala (SE).

(74) Agents: **GE HEALTHCARE BIO-SCIENCES AB** et al.; Patent Department, Björkgatan 30, S-751 84 Uppsala (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2011/123029 A1

(54) Title: METHOD FOR DETERMINATION OF BINDING STOICHIOMETRY

(57) Abstract: A method is provided for determining binding stoichiometry for the interaction between a first molecule and a second molecule forming a complex between them. Either (i) a solution having a fixed initial active concentration of the first molecule is titrated with solutions of varying active concentrations of the second molecule, and the free active concentrations of the second molecule are measured; or (ii) a solution with fixed initial concentrations of the first molecule and the second molecule is incubated, and the free active concentrations of both molecules are measured. In the first case, the binding stoichiometry can be determined from the initial concentration values of both molecules and the free concentration value(s) of the second molecule at saturation; and in the second case from the initial concentration values of both molecules and the free concentration values of both molecules. Active concentration measurements are typically performed by an interaction analysis sensor, using a calibration-free analytical format at least for the determination of active initial concentrations.

METHOD FOR DETERMINATION OF BINDING STOICHIOMETRY

Field of the invention

The present invention relates to a method for the determination of stoichiometry of
5 binding between two binding partners, such as, for example, a receptor and a ligand.

Background of the invention

The number of binding sites involved when two molecules interact, i.e. the binding
stoichiometry, is many times of fundamental interest, since it is related to molecular
10 function. The binding stoichiometry can be measured directly, for instance by
determining the molecular weight of the formed complex, or it can be measured by
indirect methods provided that the concentrations of both interacting molecules, or
binding partners, are known.

15 Prior art indirect methods for determining stoichiometry of binding typically use
spectrophotometric methods, such as UV or NIR absorption spectrometry, or
fluorescence-based detection for determining the total concentration of a molecule.

US 6,025,142 A discloses determination of the stoichiometry and affinity of the
20 binding of the fluorophore 8-anilino-1-naphthalene sulfonate (ANS) to urokinase-type
plasminogen activator (u-PA) by titrating fixed concentrations of u-PA with ANS up
to a concentration of 100 μM . The theoretical fluorescence of a molar solution if all
were bound to u-PA was calculated by titration of a protein concentration
sufficiently high to ensure that all added ANS is bound in the initial part of the
25 binding curve. The generated data were analyzed by the method of Scatchard.

US 2005-0037377 A discloses a method for determining the binding affinity and/or
stoichiometry of a binding complex between a binding factor and a probe using
fluorescence techniques. The method comprises: (a) labeling the probe with a
30 fluorophore; (b) incubating the labeled probe with a factor or a group of factors which
may bind the labeled probe to form a binding complex; (c) separating the binding
complex and the free probe into different fractions; (d) subjecting each fraction from
step (c) to fluorescence polarization measurement under conditions wherein the
binding complex produces a fluorescence pattern different from that of the free probe,
35 thereby allowing detection of the binding complex; and (e) determining binding affinity

and/or stoichiometry between the probe and the binding factor. Typically, the binding complex formation is monitored by fluorescence polarization detection.

Zhi-Xin Wang, et al., *Anal. Biochem.* 206 (1992): 376–381 discloses a titration protocol
5 for determining the dissociation constant and binding stoichiometry of a protein-
ligand complex, detectable by spectroscopic methods. In this procedure, a fixed
concentration of protein (or ligand) is titrated by increasing volumes of a stock ligand
(or protein) solution, and the changes in the spectroscopic signal are recorded after
each addition of the titrant. The signal for interaction between protein and ligand first
10 increases, reaches a maximum value, and then starts decreasing due to dilution
effect. The volume of the titrant required to achieve the maximum signal changes is
utilized to calculate the dissociation constant and the binding stoichiometry of the
protein-ligand complex according to the theoretical relationships developed herein.
Specifically, the interaction of avidin with a chromophoric biotin analogue, 2-(4'-
15 hydroxyazobenzene)benzoic acid, was studied by following the absorption signal of
their interaction at 500 nm.

These methods do, however, not distinguish between active and inactive molecules.
Since only active molecules contribute to binding in the interaction studied, total
20 molecule concentration will therefore only provide an estimate of the total
concentration of a molecule which may differ substantially from the concentration of
“active” molecules. As is readily seen, this can be a substantial dilemma when
determining binding stoichiometry by indirect methods.

25 It is an object of the present invention to provide a method which overcomes the
deficiencies of the prior art methods and provides for accurate determination of
binding stoichiometry by indirect methods even in case of molecule solutions which
may contain substantial amounts of inactive interactant molecules.

30 **Summary of the invention**

According to the present invention, binding stoichiometry is determined based on
determination of active molecule concentrations rather than total molecule
concentrations.

35 The method of the present invention for determining binding stoichiometry is defined
in independent claim 1.

In one variant, a method for determining binding stoichiometry for the interaction between a first molecular species and a second molecular species forming a complex between them comprises the steps of:

- a) preparing a solution containing predetermined initial active concentrations of the first molecular species and the second molecular species, wherein the initial active concentration of the second molecular species is selected to be sufficient to cause saturation of the binding of the second molecular species to the first molecular species;
- b) determining the free active concentration of the second molecular species;
- 10 c) determining the ratio of the difference between the initial active concentration and the free active concentration of the second molecular species to the initial active concentration of the first molecular species, or *vice versa*; and
- d) determining from said ratio the binding stoichiometry for the interaction.

15 In a preferred embodiment of this method variant, the fact that saturation of the binding of the second molecular species to the first molecular species is present is ensured by titrating a fixed active concentration of the first molecular species with varying active concentrations of the second molecular species. Steps a) to c) above may then be performed by providing a plurality of solutions, wherein each solution
20 contains a fixed predetermined concentration of the first molecular species and a varying predetermined concentration of the second molecular species. The free active concentration of the second molecular species is determined for each solution, and the respective differences between initial active concentration and free active concentration of the second molecular species are calculated. By relating, e.g.
25 plotting, each calculated difference to a respective initial active concentration, the saturation level for this difference (between initial active concentration and free active concentration of the second molecular species) can be determined, which is then used in step d).

30 In another variant, the method comprises the steps of:

- a) preparing a solution of the first molecular species and the second molecular species having predetermined initial active concentrations of the respective molecular species;
- b) determining the free active concentration of the first molecular species;
- 35 c) determining the free active concentration of the second molecular species;

d) determining the ratio of the difference between the initial active concentration and the free active concentration of the second molecular species to the difference between the initial active concentration and the free active concentration of the first molecular species, or *vice versa*; and

5 e) determining from said ratio the binding stoichiometry for the interaction.

Determination of active concentration is preferably performed using an interaction analysis sensor, which typically comprises a sensing surface supporting a specific binding partner to the molecular species whose active concentration is to be
10 determined. After contacting the sensing surface with the molecular species, the association/dissociation process at the surface is monitored.

Preferably, the determination of at least initial active concentration comprises contacting the solution with a sensor surface at varying flow rates under conditions of
15 at least partial mass transport limitation, whereby the use of a calibration standard will not be required.

Further preferred embodiments of the invention are set forth in the dependent claims.

20 A more complete understanding of the present invention, as well as further features and advantages thereof, will be obtained by reference to the following detailed description and the accompanying drawings.

Brief description of the drawings

25 Figure 1 is a diagram showing a plot of $(B_{tot} - B_{free})$ versus B_{tot} for a simulated procedure according to an embodiment of the method of the present invention.

Detailed description of the invention

Unless defined otherwise, all technical and scientific terms used herein have the same
30 meaning as commonly understood by a person skilled in the art related to this invention. Also, the singular forms "a", "an", and "the" are meant to include plural reference unless it is stated otherwise.

As mentioned above, the present invention relates to the determination of the
35 stoichiometry of binding between two interacting molecules, for example a receptor and a ligand, such that a complex between the molecules is formed. In brief, the

method is based on determining initial active concentrations of the interacting molecules and active concentrations of free (non-complexed) molecules of one or both molecules after complex formation has been initiated, and based on the resulting data determining the binding stoichiometry for the interaction.

5

Further examples of interacting molecule pairs include antibody/antigen.

In one embodiment, the determination of the stoichiometry of the binding between two molecules A and B which may interact to form a complex AB comprises the following steps:

10

1) incubation of molecules A and B in solution with a fixed initial active concentration of one binding partner (A_{tot}) that is titrated with varying initial active concentrations of the other binding partner (B_{tot});

15

2) determination of active concentration of free binding partner B (B_{free}) in each mixture;

3) identification of the saturation value(s) for ($B_{tot}-B_{free}$) from plots of ($B_{tot}-B_{free}$) vs B_{tot} , ($B_{tot}-B_{free}$) by definition being the concentration of B molecules in complex with A;

20

4) determination of the number of binding sites on A for B from the expression ($B_{tot}-B_{free}$)_{at saturation}/ A_{tot} .

Of course, in the procedure outlined above, molecules A and B are interchangeable, i.e., instead, molecule B may be in a fixed active concentration and titrated with varying active concentrations of molecule A.

25

In another embodiment, which assumes that A_{free} and B_{free} can both be accurately determined for any interaction mixture, the stoichiometry can be determined by studying the ratio of molecules in the complex formed when incubating fixed concentrations of molecules A and B in solution, i.e. by calculating the ratio ($B_{tot}-B_{free}$)/($A_{tot}-A_{free}$). This will provide a "snapshot" of complex stoichiometry for these conditions which, however, may differ from the step determination since sites of different affinity on molecule A need not be populated at the same time. Optionally, measurements may be performed on two or more different mixtures of molecules A and B to obtain a more accurate stoichiometry value.

35

The determination of active concentration of molecules A and B is preferably performed using an interaction analysis sensor, typically a biosensor. Such biosensor-based determination of active concentration is described in, for example Karlsson, R., et al. (1993) *J. Immunol. Methods* 166(1):75-84; Richalet-Sécordel, P. M., et al. (1997) *Anal Biochem.* 249(2):165-73; and Sigmundsson K., et al. (2002) *Biochemistry* 41(26):8263-76. The full disclosures of these references are incorporated by reference herein.

The interaction analysis sensor typically comprises a sensing surface(s) having immobilized thereon a specific binding partner for the molecule whose active concentration is to be determined.

In a development of the determination of active concentration using sensor technology, analyte concentrations can be determined without reference to a calibration standard. This method, which is usually referred to as Calibration-Free Concentration Analysis (CFCA), relies upon measurement of analyte binding to a target immobilized on a sensor surface at varying flow rates under conditions where the observed rate of binding is partially or completely limited by transport of analyte molecules to the sensor surface, i.e. partially or completely controlled by diffusion. CFCA will be described in more detail further below. First, however, the concept of biosensors will be briefly described.

A biosensor is typically based on label-free techniques, detecting a change in a property of a sensor surface, such as mass, refractive index or thickness of the immobilized layer. Typical biosensors for the purposes of the present invention are based on mass detection at the sensor surface and include especially optical methods and piezoelectric or acoustic wave methods. Representative sensors based on optical detection methods include those that detect mass surface concentration, such as sensors based on reflection-optical methods, including e.g. evanescent wave-based sensors including surface plasmon resonance (SPR) sensors, frustrated total reflection (FTR) sensors, and waveguide sensors, including e.g. reflective interference spectroscopy (RIFS) sensors. Piezoelectric and acoustic wave sensors include surface acoustic wave (SAW) and quartz crystal microbalance (QCM) sensors.

Biosensor systems based on SPR and other detection techniques are commercially available today. Exemplary such SPR-biosensors include the flow-through-cell-based

Biacore® systems (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and ProteOn™ XPR system (Bio-Rad Laboratories, Hercules, CA, USA) which use surface plasmon resonance for detecting interactions between molecules in a sample and molecular structures immobilized on a sensing surface or surfaces. As sample is passed over the sensing surface, the progress of binding directly reflects the rate at which the interaction occurs. Injection of sample is usually followed by a buffer flow during which the detector response reflects the rate of dissociation of the complex on the surface. A typical output from the system is a graph or curve describing the progress of the molecular interaction with time, including an association phase part and a dissociation phase part. This binding curve, which is usually displayed on a computer screen, is often referred to as a "sensorgram".

With the Biacore® systems it is thus possible to determine in real time without the use of labeling, and often without purification of the substances involved, not only the presence and concentration of a particular molecule, or analyte, in a sample, but also additional interaction parameters, including kinetic rate constants for association (binding) and dissociation in the molecular interaction as well as the affinity for the surface interaction.

In the following, the present invention will to a large extent be described, for illustration only and no limitation, with regard to SPR-sensors of the Biacore® system type.

The Biacore® systems, as well as analogous sensor systems, measure the active analyte concentration as distinct from the total concentration of the analyte. As to the term "active", it is the choice of ligand on the sensor surface that defines the kind of activity being measured. While e.g. standard protein concentration analysis using a calibration curve may be used, the Biacore® systems (and analogous sensor systems) permit assessment of protein (and e.g. other macromolecule) concentration by a calibration-free method, which is often referred to as calibration-free concentration analysis (CFCA).

The method relies on changes in binding rates of analyte to a target (ligand) immobilized on a surface with varying flow rates under conditions of partial or total mass transport and does, as mentioned, not require standards of known concentrations, given that the diffusion coefficient is known or is estimated from the

molecular mass of the molecule of interest. For a more detailed description such calibration-free measurement it may be referred to, for example, the above-mentioned Sigmundsson, K., et al. (2002) *Biochemistry* 41(26): 8263-8276.

5 In Biacore® instruments, or analogous instruments, samples are injected in a micro-flow system and transported in a laminar flow to the sensor surface. Molecules reach the sensor surface from bulk solution by a diffusion-controlled transport process. In addition to the concentration of analyte molecules, factors influencing the transport include the diffusion coefficient, flow cell dimensions and flow rate. The balance
10 between the transport rate and the binding rate determines whether the observed binding will be transport limited or reaction limited.

For successful CFCA, the observed binding rate must be at least partially limited by transport. The concentration is obtained by running the binding experiments at at
15 least two different flow rates and fitting the data to a model describing the process, e.g. a two-compartment model (Myszka, D. G., et al. (1998) *Biophys. J.* 75, 583-594, and Schank-Retzlaff, M. L. and Sligar, S. G. (2000) *Anal. Chem.* 72, 4212-4220). For a more comprehensive description of curve fitting with regard to the Biacore® systems, it may be referred to the BIAevaluation™ Software Handbook (GE Healthcare Bio-
20 Sciences AB, Uppsala, Sweden).

The binding of analyte to surface-attached ligand in a controlled flow system is represented by the sum of two processes, transport of analyte to the surface and molecular interaction with the immobilized ligand. The molecular interaction is
25 described by the rate constants k_a and k_d , while transport of analyte to and from the surface is described by the mass transport constants k_m and k_{-m} (also referred to as k_t and k_{-t}). The transport phenomenon is symmetrical since this is essentially a diffusion-limited process, so $k_m=k_{-m}$.

30 Thus, for determining active concentration of, for example, a protein using a Biacore® system (or analogous), a protein solution is injected at least twice (different flow rates) over the surface with immobilized interaction partner. The binding phases of the sensorgrams obtained from such an experiment are fitted to a bi-molecular interaction model with mass transfer term, in which the active concentration is a
35 fitted parameter. The fitting is preferably global, i.e. the interaction model is fitted simultaneously to multiple binding curves (sensorgrams). In this model, the value of

the mass transport coefficient is introduced as a constant, which, as described above, may be calculated from the dimensions of the flow cell, the diffusion coefficient of the protein and the flow rate used.

- 5 In a simplified form, the response increase dR/dt at the sensor surface given by bound protein is proportional to the mass transport constant k_t and the active concentration, i.e.

$$dR/dt = k_t \cdot (\text{active concentration}) \quad (2)$$

10

k_t can be re-written as $\text{constant} \cdot Mw \cdot D^{2/3}$, where Mw is the molecular weight of the protein and D is its diffusion coefficient, which gives

$$dR/dt = \text{constant} \cdot Mw \cdot D^{2/3} \cdot (\text{active concentration}) \quad (3)$$

15

The diffusion coefficient D is a function of the size and shape of the molecule and the frictional resistance offered by the viscosity of the solvent in question. For spherical molecules, the diffusion coefficient is inversely proportional to the radius and thus proportional to the cube root of the molecular weight. For very large solute molecules, such as proteins, however, the diffusion coefficient is relatively insensitive to the molecular weight.

20

Now turning to the present invention again, to measure active concentrations of the molecules A and B with a Biacore™ type sensor instrument, specific binding partners to the respective molecules are provided for immobilization on a sensing surface of the sensor instrument.

25

To carry out the above first-mentioned method variant involving titration, respective stock solutions containing molecules A and B are prepared, and the active concentrations of molecules A and B are determined using CFCA and sensing surfaces with immobilized binding partner to molecules A and B, respectively. A number of solution mixtures are then prepared from the stock solutions which contain a fixed concentration of molecule A and varying concentrations of the molecule B. The initial concentrations of molecules A and B (A_{tot} and B_{tot} , respectively), i.e. the concentrations before any interaction has taken place, may be calculated from the volumes of stock solutions used. After incubation, the active

30
35

concentrations of molecule B in the different mixtures are determined using a sensing surface(s) with immobilized binding partner to molecule B and either (i) CFCA, or (ii) a standard or calibration curve (prepared using the active concentration determined by CFCA for the stock solution of B). Based on the results of the concentration
5 measurements, the binding stoichiometry for the molecular interaction may then be determined as described further above.

When titrating a fixed active concentration of one binding partner with varying active concentrations of the other binding partner as described above, the different solution
10 mixtures are prepared before being injected into the biosensor instrument, or, optionally, solutions of the respective interactants in known active concentrations may be injected into the biosensor instrument to be mixed in predetermined proportions within the instrument, as described in, for example, WO 2008/033073 (the full disclosure of which is incorporated by reference herein).

15 The above-mentioned other method variant, including determination of free active concentrations of molecules A and B after incubation, may be performed in an analogous manner.

20 In the following Example, a simulation of a procedure for the determination of binding stoichiometry according to the method of the present invention will be described.

Example

A simulation of the stoichiometry for the binding interaction between two molecules A
25 and B (forming a complex AB) is presented in Table 1 below. The input data were as follows:

Total concentration of A:	5,00E-07
Total concentration of B:	1,00E-09
30 Affinity:	1,00E-06

Table 1

A total (M)	B total (M)	KD	Complex formed	Free A	Atot-Afree	Free B	Btot-Bfree	(Atot-Afree)/(Btot-Bfree)
5,00E-07	1,00E-09	1,00E-06	3,33E-10	5,00E-07	3,33E-10	6,67E-10	3,33E-10	1,0
5,00E-07	3,00E-09	1,00E-06	9,99E-10	4,99E-07	9,99E-10	2,00E-09	9,99E-10	1,0
5,00E-07	9,00E-09	1,00E-06	2,99E-09	4,97E-07	2,99E-09	6,01E-09	2,99E-09	1,0
5,00E-07	2,70E-08	1,00E-06	8,89E-09	4,91E-07	8,89E-09	1,81E-08	8,89E-09	1,0
5,00E-07	8,10E-08	1,00E-06	2,6E-08	4,74E-07	2,60E-08	5,50E-08	2,60E-08	1,0
5,00E-07	2,43E-07	1,00E-06	7,27E-08	4,27E-07	7,27E-08	1,70E-07	7,27E-08	1,0
5,00E-07	7,29E-07	1,00E-06	1,78E-07	3,22E-07	1,78E-07	5,51E-07	1,78E-07	1,0
5,00E-07	2,19E-06	1,00E-06	3,25E-07	1,75E-07	3,25E-07	1,86E-06	3,25E-07	1,0
5,00E-07	6,56E-06	1,00E-06	4,3E-07	7,01E-08	4,30E-07	6,13E-06	4,30E-07	1,0
5,00E-07	1,97E-05	1,00E-06	4,75E-07	2,47E-08	4,75E-07	1,92E-05	4,75E-07	1,0
5,00E-07	5,90E-05	1,00E-06	4,92E-07	8,40E-09	4,92E-07	5,86E-05	4,92E-07	1,0
5,00E-07	1,77E-04	1,00E-06	4,97E-07	2,81E-09	4,97E-07	1,77E-04	4,97E-07	1,0
5,00E-07	5,31E-04	1,00E-06	4,99E-07	9,40E-10	4,99E-07	5,31E-04	4,99E-07	1,0
5,00E-07	1,59E-03	1,00E-06	5E-07	3,14E-10	5,00E-07	1,59E-03	5,00E-07	1,0
5,00E-07	4,78E-03	1,00E-06	5E-07	1,05E-10	5,00E-07	4,78E-03	5,00E-07	1,0
5,00E-07	1,43E-02	1,00E-06	5E-07	3,48E-11	5,00E-07	1,43E-02	5,00E-07	1,0
5,00E-07	4,30E-02	1,00E-06	5E-07	1,16E-11	5,00E-07	4,30E-02	5,00E-07	1,0
5,00E-07	1,29E-01	1,00E-06	5E-07	3,87E-12	5,00E-07	1,29E-01	5,00E-07	1,0
5,00E-07	3,87E-01	1,00E-06	5E-07	1,29E-12	5,00E-07	3,87E-01	5,00E-07	1,0
5,00E-07	1,16E+00	1,00E-06	5E-07	4,30E-13	5,00E-07	1,16E+00	5,00E-07	1,0

Using values from the simulation data above, Btot-Bfree was plotted against Btot, the
 5 resulting graph being shown in Figure 1. As is readily seen, in an unknown case (i.e. KD and binding mechanism are unknown), such a plot will reveal binding stoichiometry (in the illustrated case 1:1).

A determination of stoichiometry according to the invention may, for example, be
 10 performed using a Biacore™ system, e.g. a Biacore® T100 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), wherein a micro-fluidic system passes samples and running buffer through four individually detected flow cells (one by one or in series).

As sensor chip may, for example, be used Series S Sensor Chip CM5 (GE Healthcare
 15 Bio-Sciences AB) which has a gold-coated surface with a covalently carboxymethyl-modified dextran polymer hydrogel. The output from the instrument is a "sensorgram" which is a plot of detector response (measured in "resonance units", RU) as a function of time. An increase of 1000 RU corresponds to an increase of mass on the sensor surface of approximately 1 ng/mm².

20 For calculations, the dedicated BIAevaluation Software and Biacore T100 Software 2.0 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) may be used, which includes a module for calibration-free concentration analysis (CAFC).

A procedure for determining the number of binding sites on a molecule A for molecule B using a Biacore® T100 may be performed as follows:

A Determination of active concentrations

- 5 1) Insert sensor chip CM5 and prime the system with buffer.
- 2) Immobilize molecule A in flow cell 2 and molecule B in flow cell 4.
Aim to immobilize between 25 and 100 RU/kDa. (That is, if molecule A has a molecular weight of 50 kDa, immobilize between 1250 and 5000 RU).
- 3) Inject molecule B over immobilized ligand A and use a dilution that gives an initial
10 binding rate of at least 0,3 RU/s at a flow rate of 5 µl/min. Use an injection time of 60 s.
- 4) Inject the same dilution of molecule B at a flow rate of 100 µl/min also for 60 s.
- 5) In the same manner as described in steps 3 and 4, inject molecule A over immobilized ligand B at 5 and 100 µl/min.
- 15 6) Open T100 evaluation software and determine the concentration of molecules A and B with the analysis tool Concentration analysis/Calibration free.

B) Determination of stoichiometry

20 With knowledge of the active concentration of molecules A and B, the stoichiometry of binding can now be determined.

- 1) Use a fix concentration "2a" of molecule A and pipette 100 µl of that solution into at least 10 wells of a 96 well plate.
- 2) Prepare a 200 µl solution of molecule B at concentration 100*2a (or higher) and prepare 10 (or more) successive three-fold dilutions of B.
- 25 These solutions are to be used in a standard curve for determination of the free concentration of B and for incubation with molecule A.
- 3) Transfer 100 µl of each B solution to a well where molecule A is already present at concentration "2a", giving an initial concentration "a" of molecule A.
- 4) Inject standard concentrations of B over immobilized ligand A.
- 30 5) Inject solutions of A incubated with varying concentrations of B over immobilized ligand A.
In steps 4 and 5, a typical injection time could be 3 minutes and a typical flow rate 10 µl/min. Use a report point set 10 seconds after injection stop as response value.
- 6) Open T100 evaluation software and prepare a standard curve for B by plotting the
35 response value obtained from the injection versus the known concentration of B.
- 7) Determine the free concentration of B in each mixture.

8) Plot (B_{tot}-B_{free}) vs B_{tot} and use data points at saturation (see Fig 1) to calculate the stoichiometry from the expression $\text{stoichiometry} = (\mathbf{B_{tot}-B_{free}})_{\text{at saturation}}/\mathbf{A_{tot}}$.

The present invention is not limited to the above-described preferred embodiments.

5 Various alternatives, modifications and equivalents may be used. Therefore, the above embodiments should not be taken as limiting the scope of the invention, which is defined by the appending claims.

Claims

1. A method of determining binding stoichiometry for the interaction between a first molecular species and a second molecular species forming a complex
5 between them, comprising the steps of:
- a1) preparing a solution containing predetermined initial active concentrations of the first molecular species and the second molecular species, wherein the initial active concentration of the second molecular species is selected to be sufficient to cause saturation of the binding of the second molecular species to the
10 first molecular species,
- a2) determining the free active concentration of the second molecular species,
a3) determining the ratio of the difference between the initial active concentration and the free active concentration of the second molecular species to the initial active concentration of the first molecular species, and
15 a4) determining from said ratio the binding stoichiometry for the interaction;
or
b1) preparing a solution of the first molecular species and the second molecular species having predetermined initial active concentrations of the respective molecular species,
20 b2) determining the free active concentration of the first molecular species,
b3) determining the free active concentration of the second molecular species,
b4) determining the ratio of the difference between the initial active concentration and the free active concentration of the second molecular species to the difference between the initial active concentration and the free active concentration of
25 the first molecular species, and
b5) determining from said ratio the binding stoichiometry for the interaction.
2. The method according to claim 1, wherein steps a1) to a3) comprise the steps of preparing a plurality of solutions, each solution containing a fixed
30 predetermined concentration of the first molecular species and a varying predetermined concentration of the second molecular species, determining for each solution the free active concentration of the second molecular species, calculating for each solution the difference between the initial active concentration and free active concentration of the second molecular species, and relating each difference to a
35 respective initial active concentration to determine a saturation level for the difference, which is used in step a4).

3. The method according to claim 1 or 2, wherein active concentrations of said molecular species are determined using an interaction analysis sensor.

5 4. The method according to claim 3, wherein the interaction analysis sensor comprises a sensing surface supporting a specific binding partner to the molecular species whose active concentration is to be determined.

10 5. The method according to claim 4, wherein the determination of at least said predetermined active concentrations comprises contacting a solution containing the molecule to be determined with a sensor surface at varying flow rates under conditions of at least partial mass transport limitation.

15 6. The method according to claim 5, wherein the determination of active concentration is performed without the use of a calibration standard.

7. The method according to any one of claims 1 to 6, wherein the interaction analysis sensor is a biosensor.

20 8. The method according to claim 7, wherein the biosensor is a mass-sensing biosensor, preferably a biosensor based on evanescent wave sensing, especially surface plasmon resonance (SPR).




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2011/050343

A. CLASSIFICATION OF SUBJECT MATTER		
IPC: see extra sheet		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC: G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE, DK, FI, NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-Internal, PAJ, WPI data, BIOSIS, COMPENDEX, EMBASE, INSPEC, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Day et al. " Selectivity of BAFF/BlyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.", Biochemistry, 2005, vol 44, nr 66, sid 1919-1931, ISSN 0006-2960; abstract; See pp 1922-1923 and 129 --	1-8
A	Lin et al. "Determination of binding constant and stoichiometry for antibody-antigen interaction with surface plasmon resonance" Current Proteomics, 2006, vol 3, nr 4, sid 271-282, ISSN 1570-1646; abstract --	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 20-07-2011		Date of mailing of the international search report 20-07-2011
Name and mailing address of the ISA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86		Authorized officer Carolina Gomez Lagerlöf Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2011/050343

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Wang et al. "A novel spectroscopic titration method for determining the dissociation constant and stoichiometry of protein-ligand complex" ANALYTICAL BIOCHEMISTRY, 1992, vol 206, nr 2, sid 376-381; abstract --	1-8
A	Chu et al. "Using affinity capillary electrophoresis to determine binding stoichiometries of protein-ligand interactions", Biochemistry, 1994,33, 10616-10621; abstract; pages 10619-10620 -- -----	1-8

Continuation of: second sheet
International Patent Classification (IPC)
G01N 33/543 (2006.01)